BR0211910A - Derivados de tiazolila 2,4,5-trissubstituìdos e a atividade antiinflamatória dos mesmos - Google Patents
Derivados de tiazolila 2,4,5-trissubstituìdos e a atividade antiinflamatória dos mesmosInfo
- Publication number
- BR0211910A BR0211910A BR0211910-2A BR0211910A BR0211910A BR 0211910 A BR0211910 A BR 0211910A BR 0211910 A BR0211910 A BR 0211910A BR 0211910 A BR0211910 A BR 0211910A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- aminocarbonyl
- mono
- amino
- optionally substituted
- Prior art date
Links
- -1 2,4,5-trisubstituted thiazolyl Chemical class 0.000 title abstract 3
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
Abstract
"DERIVADOS DE TIAZOLILA 2,4,5-TRISSUBSTITUìDOS E A ATIVIDADE ANTIINFLAMATóRIA DOS MESMOS". A presente invenção refere-se ao uso de um composto da fórmula (I), um N-óxido, um sal de adição farmaceuticamente aceitável, uma amina quaternária e uma forma estereoquimicamente isomérica do mesmo, no qual Z é haio; C~ 1-6~alquila; C~ 1-6~alquila substituída com hidróxi, carboxila, ciano, amino, mono- ou di(C~ 1-6~alquil)amino, aminocarbonila, mono- ou di(C~ 1-6~alquil)aminocarbonila, C~ 1-6~-alquiloxicarbonila ou C~ 1-6~alquilóxi; polihaloC~ 1-4~alquila; C~ 1-4~alquilóxi; ciano; amino; aminocarbonila; mono- ou di(C~ 1-6~alquil)aminocarbonila); C~ 1-6~alquiloxicarbonila; C~ 1-6~alquilcarbonilóxi; H~ 2~N-S(=0)~ 2~; mono-ou di(C~ 1-6~alquil)amino-S(=0)~ 2; -C(=N-Rx)NR~^ Y^R^ z^; Q é um carbociclo opcionalmente substituído ou um heterociclo opcionalmente substituído; L é fenila substituída ou um heterociclo monocíclico opcionalmente substituído de 5 ou 6 membros parcialmente saturado ou aromático ou um heterociclo bicíclico, parcialmente saturado ou aromático; arila é fenila opcionalmente substituída; para a produção de um medicamento para a prevenção ou tratamento de doenças mediadas através de TNF-<244> e/ou IL-12.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01203088 | 2001-08-13 | ||
| PCT/EP2002/008956 WO2003015776A1 (en) | 2001-08-13 | 2002-08-09 | 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0211910A true BR0211910A (pt) | 2004-10-19 |
Family
ID=8180791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0211910-2A BR0211910A (pt) | 2001-08-13 | 2002-08-09 | Derivados de tiazolila 2,4,5-trissubstituìdos e a atividade antiinflamatória dos mesmos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7138403B2 (pt) |
| EP (1) | EP1418911B1 (pt) |
| JP (1) | JP4491231B2 (pt) |
| KR (1) | KR100922538B1 (pt) |
| CN (1) | CN100502863C (pt) |
| AR (1) | AR037232A1 (pt) |
| AT (1) | ATE325608T1 (pt) |
| AU (1) | AU2002331227B2 (pt) |
| BR (1) | BR0211910A (pt) |
| CA (1) | CA2451981C (pt) |
| DE (1) | DE60211348T2 (pt) |
| EA (1) | EA007933B1 (pt) |
| ES (1) | ES2264734T3 (pt) |
| HR (1) | HRP20040098B1 (pt) |
| HU (1) | HUP0401160A3 (pt) |
| IL (2) | IL160327A0 (pt) |
| MX (1) | MXPA04001400A (pt) |
| MY (1) | MY130780A (pt) |
| NO (1) | NO327345B1 (pt) |
| NZ (1) | NZ530772A (pt) |
| PL (1) | PL210475B1 (pt) |
| TW (1) | TWI268152B (pt) |
| UA (1) | UA79756C2 (pt) |
| WO (1) | WO2003015776A1 (pt) |
| ZA (1) | ZA200401164B (pt) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| US7560568B2 (en) | 2004-01-28 | 2009-07-14 | Smithkline Beecham Corporation | Thiazole compounds |
| WO2006038734A1 (en) * | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
| WO2006041405A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-pyrimidones and uses thereof |
| US20090221579A1 (en) * | 2004-10-15 | 2009-09-03 | Jeffrey Scott Albert | Substituted Amino-Compounds and Uses Thereof |
| US20100130473A1 (en) * | 2005-02-25 | 2010-05-27 | Marc Geoffrey Hummersone | Compounds |
| BRPI0616655A2 (pt) * | 2005-10-03 | 2011-06-28 | Ono Pharmaceutical Co | composto heterocìclico contendo nitrogênio e aplicação farmacêutica do mesmo |
| AR069146A1 (es) * | 2007-11-01 | 2009-12-30 | Actelion Pharmaceuticals Ltd | Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario. |
| JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用 |
| TWI403506B (zh) * | 2008-06-16 | 2013-08-01 | Faes Farma Sa | 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類 |
| MX2011000477A (es) | 2008-07-17 | 2011-03-15 | Bayer Cropscience Ag | Compuestos heterociclicos como pesticidas. |
| KR101406433B1 (ko) | 2008-09-22 | 2014-06-13 | 카이맨 케미칼 컴파니 인코포레이티드 | Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도 |
| US8314130B2 (en) | 2008-10-01 | 2012-11-20 | Synta Pharmaceuticals Corp. | Compounds inclunding substituted pyridines for inflammation and immune-related uses |
| CN101391984B (zh) * | 2008-11-07 | 2010-12-08 | 东华大学 | 碳酸二甲酯对含巯基的嘧啶杂环化合物进行甲基化的方法 |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9090601B2 (en) * | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| CA2750935A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| CN102971315B (zh) * | 2010-05-05 | 2015-07-22 | 拜耳知识产权有限责任公司 | 作为害虫防治剂的噻唑衍生物 |
| BR112013003358A2 (pt) | 2010-08-11 | 2016-07-12 | Millennium Pharm Inc | heteroaris e seus usos |
| US8859768B2 (en) | 2010-08-11 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MX2013004003A (es) | 2010-10-13 | 2013-10-01 | Millenium Pharmaceuticals Inc | Heteroarilos y usos de los mismos. |
| US20120129843A1 (en) * | 2010-11-18 | 2012-05-24 | Yan Zhang | Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| WO2012109573A1 (en) * | 2011-02-11 | 2012-08-16 | Purdue Research Foundation | Substituted thiazoles for use as antiviral agents |
| WO2014025976A1 (en) | 2012-08-10 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| US20150284380A1 (en) * | 2012-10-31 | 2015-10-08 | Bayer Cropscience Ag | Novel heterocyclic compounds as pest control agents |
| EP2925744B1 (en) | 2012-11-27 | 2020-12-30 | Thomas Helledays Stiftelse För Medicinsk Forskning | Pyrimidine-2,4-diamine derivatives for treatment of cancer |
| WO2015116485A1 (en) | 2014-01-29 | 2015-08-06 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as btk inhibitors |
| AU2015268961B9 (en) | 2014-06-04 | 2019-10-10 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of cancer |
| US10064869B2 (en) | 2014-06-04 | 2018-09-04 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions |
| JOP20200117A1 (ar) | 2014-10-30 | 2017-06-16 | Janssen Pharmaceutica Nv | كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t |
| TR201820513T4 (tr) | 2014-10-30 | 2019-02-21 | Janssen Pharmaceutica Nv | Roryt modülatörleri olarak tiazoller. |
| ES2767303T3 (es) * | 2014-10-30 | 2020-06-17 | Janssen Pharmaceutica Nv | Tiazoles sustituidos por amida como moduladores de Rorgamma T |
| ES2897910T3 (es) | 2015-12-16 | 2022-03-03 | Boehringer Ingelheim Int | Derivados bipirazolilo útiles para el tratamiento de enfermedades autoinmunitarias |
| WO2017123695A1 (en) | 2016-01-13 | 2017-07-20 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| US10414759B2 (en) * | 2017-05-08 | 2019-09-17 | Purdue Research Foundation | Phenylthiazoles and uses thereof |
| US10975037B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of RORγt |
| ES2929140T3 (es) | 2018-06-18 | 2022-11-25 | Janssen Pharmaceutica Nv | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat |
| CN112292183A (zh) | 2018-06-18 | 2021-01-29 | 詹森药业有限公司 | 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑 |
| JP2021529161A (ja) | 2018-06-18 | 2021-10-28 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレーターとしてのピリジニルピラゾール |
| CN110746325A (zh) * | 2018-07-24 | 2020-02-04 | 上海和辉光电有限公司 | 一种基于胍骨架的n型掺杂化合物及其应用 |
| SG11202112229UA (en) | 2019-05-05 | 2021-12-30 | Qilu Regor Therapeutics Inc | Cdk inhibitors |
| CN110452224B (zh) * | 2019-08-30 | 2022-06-03 | 西南大学 | 嘧啶唑醇类化合物及其制备方法和应用 |
| WO2022155941A1 (en) * | 2021-01-25 | 2022-07-28 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE258165C (pt) | ||||
| US3499762A (en) | 1966-11-03 | 1970-03-10 | Eastman Kodak Co | Photographic elements comprising novel u.v.-absorbing optical brightening agents |
| DE1959307A1 (de) | 1969-11-26 | 1971-06-03 | Basf Ag | Optische Aufheller |
| BE795907A (fr) * | 1972-02-25 | 1973-06-18 | Luso Farmaco Inst | 2-amino-4-arylthiazoles 5-substitues et leur preparation |
| US4649146A (en) | 1983-01-31 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives and pharmaceutical composition comprising the same |
| JPH03144612A (ja) | 1989-10-31 | 1991-06-20 | Nec Corp | 接続方法 |
| JPH04368375A (ja) * | 1991-06-17 | 1992-12-21 | Otsuka Pharmaceut Factory Inc | イソオキサゾール誘導体 |
| US5240929A (en) * | 1992-08-03 | 1993-08-31 | Warner-Lambert Company | 2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents |
| JPH10504542A (ja) | 1994-07-27 | 1998-05-06 | ジー．ディー．サール アンド カンパニー | 炎症処置用の置換チアゾール化合物 |
| US5888941A (en) | 1995-08-02 | 1999-03-30 | J. Uriach & Cia. S.A. | Carbozamides with antifungal activity |
| AR008395A1 (es) * | 1996-07-09 | 2000-01-19 | Astra Pharma Prod | Compuesto derivado de pirimidina, composicion farmaceutica que lo comprende, procedimiento para prepararlo, y compuesto intermediario util parallevar a cabo dicho procedimiento. |
| AU4205197A (en) | 1996-08-26 | 1998-03-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | New thiazole derivatives with phosphodiesterase-inhibiting effect |
| AU4015497A (en) | 1996-08-26 | 1998-03-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazole derivatives useful as selective inhibitors of pde-iv |
| CA2355075C (en) * | 1998-12-16 | 2009-12-08 | Aventis Pharma Limited | Heteroaryl-cyclic acetals |
| DE10001644A1 (de) * | 1999-01-19 | 2000-07-20 | Clariant Gmbh | Fluorierte Azole und ihre Verwendung in flüssigkristallinen Mischungen |
| AU7922900A (en) | 1999-10-27 | 2001-05-08 | Novartis Ag | Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use |
| ES2222336T3 (es) * | 2000-01-18 | 2005-02-01 | Vertex Pharma | Inhibidores de girasas y sus usos. |
| US7105550B2 (en) | 2000-03-01 | 2006-09-12 | Christopher Love | 2,4-disubstituted thiazolyl derivatives |
| HUP0300382A3 (en) * | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031103D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| US7091225B2 (en) * | 2000-12-20 | 2006-08-15 | Smithkline Beecham Corporation | Substituted oxazoles and thiazoles as hPPAR alpha agonists |
-
2002
- 2002-08-09 CA CA2451981A patent/CA2451981C/en not_active Expired - Lifetime
- 2002-08-09 BR BR0211910-2A patent/BR0211910A/pt not_active IP Right Cessation
- 2002-08-09 PL PL368241A patent/PL210475B1/pl unknown
- 2002-08-09 NZ NZ530772A patent/NZ530772A/xx not_active IP Right Cessation
- 2002-08-09 AU AU2002331227A patent/AU2002331227B2/en not_active Ceased
- 2002-08-09 DE DE60211348T patent/DE60211348T2/de not_active Expired - Lifetime
- 2002-08-09 ES ES02767360T patent/ES2264734T3/es not_active Expired - Lifetime
- 2002-08-09 KR KR1020037017269A patent/KR100922538B1/ko not_active Expired - Fee Related
- 2002-08-09 CN CNB028157761A patent/CN100502863C/zh not_active Expired - Fee Related
- 2002-08-09 JP JP2003520735A patent/JP4491231B2/ja not_active Expired - Lifetime
- 2002-08-09 HU HU0401160A patent/HUP0401160A3/hu unknown
- 2002-08-09 US US10/486,820 patent/US7138403B2/en not_active Expired - Lifetime
- 2002-08-09 AT AT02767360T patent/ATE325608T1/de active
- 2002-08-09 EA EA200400305A patent/EA007933B1/ru not_active IP Right Cessation
- 2002-08-09 IL IL16032702A patent/IL160327A0/xx unknown
- 2002-08-09 HR HRP20040098AA patent/HRP20040098B1/xx not_active IP Right Cessation
- 2002-08-09 WO PCT/EP2002/008956 patent/WO2003015776A1/en not_active Ceased
- 2002-08-09 EP EP02767360A patent/EP1418911B1/en not_active Expired - Lifetime
- 2002-08-09 MY MYPI20022968A patent/MY130780A/en unknown
- 2002-08-09 MX MXPA04001400A patent/MXPA04001400A/es active IP Right Grant
- 2002-08-12 TW TW091118060A patent/TWI268152B/zh not_active IP Right Cessation
- 2002-08-12 AR ARP020103035A patent/AR037232A1/es active IP Right Grant
- 2002-09-08 UA UA2004031902A patent/UA79756C2/uk unknown
-
2004
- 2004-02-11 IL IL160327A patent/IL160327A/en active IP Right Grant
- 2004-02-12 ZA ZA2004/01164A patent/ZA200401164B/en unknown
- 2004-02-12 NO NO20040631A patent/NO327345B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0211910A (pt) | Derivados de tiazolila 2,4,5-trissubstituìdos e a atividade antiinflamatória dos mesmos | |
| RU2348617C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| BR0211887A (pt) | Derivados de triazolil 2-amino-4,5-trissubstituìdo | |
| WO2001064639A3 (en) | Pde iv inhibiting amides, compositions and pharmaceutical use | |
| DK1104760T3 (da) | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler | |
| IS6565A (is) | Trópan afleiður nytsamlegar í meðferð | |
| CY1111693T1 (el) | Αντιιικοι παραγοντες | |
| SE0104332D0 (sv) | Therapeutic agents | |
| BR0213790A (pt) | Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta | |
| BRPI0411365A (pt) | derivados de aminopiridina | |
| DK1104759T3 (da) | Heteroarylphenylpyrazolforbindelser som antiinflammatoriske/analgetiske midler | |
| ATE302775T1 (de) | Carbolinderivate | |
| AU2003284632A1 (en) | Isoquinoline compounds and medicinal use thereof | |
| NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
| ATE346067T1 (de) | Carbolinderivate | |
| EA200000400A1 (ru) | Галогензамещенные тетрациклические производные тетрагидрофурана | |
| ATE384722T1 (de) | Alkoxypyridinderivate | |
| AU2001255646A1 (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | |
| WO2000074664A3 (en) | Novel iron chelators and pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders | |
| EA200400219A1 (ru) | Производные хинолина и их использование в качестве противоопухолевых средств | |
| AU2001296677A1 (en) | Substituted (e)-styryl benzylsulfones for treating proliferative disorders | |
| UA92007C2 (ru) | Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности | |
| PT1072601E (pt) | Derivados de 4-arilpiperidina para o tratamento de prurido | |
| AP2002002707A0 (en) | 4, 5-Dihydro-Thiazo-2-Ylamine Derivatives and their Use as NO-Synthase Inhibitors. | |
| TH65449A (th) | สารยับยั้ง hiv อินทีเกรส |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2318 DE 09-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/426 (2006.01), A61K 31/427 (2006.01), A61K |